Elecsys® CYFRA 21-1 testin human serum and plasma ⁇ 19’s particles a quantitatively measured measure in vitro immunoassay test. This test, especially lung cancer is used to monitor the disease course and response to treatment of patients. Home 19It is a structural protein found in epithelium cells, and it is mixed into the blood by parting in some types of tumors.
CYFRA 21-1 levels The change in time provides important information in evaluation of the treatment activity and observing disease progregation. However, it is not the only recognizable; clinical evaluation and other laboratory methods should be interpreted together. Therefore, test, with serial measurement should be performed and integrated in the patient tracking process.
How Does Test Work And Which Technology Use?
Elecsys® CYFRA 21-1, Roche developed by electrokimiluemia immunooassay (ECLIA) works with technology. This method is used in low concentrations. CYFRA 21-1 Particles It can be identified with high accuracy. Test, Li-heparin, K2-EDTA and K3-EDTA It can be applied in stabilized plasma or serum samples.
The results of the test are reported quantitatively, and these values can be followed by comparing over time and the effectiveness of the response to which the disease is progressed or treated. ECLIA technology The high sensitivity and repeatability it offers allows clinics to make decisions safely.
Compatible Devices: Powerful and Widely Platform Support
Elecsys® CYFRA 21-1 test, Roche’s widely used cobas e series immunooassay analyzers fully compatible. Compatible devices are: cobas e 801, cobas e 402, cobas e 411, cobas e 602 and cobas e 601. Thanks to these devices, laboratories can easily process high daily sample volumes and get results quickly.
With full integration with devices, the application of the test is easy, the laboratory efficiency is also increased. In addition cobas The advantages of automation and traceability provided by the platform, Elecsys tests increases clinical reliability.
CYFRA 21-1 When and Why To Use?
CYFRA 21-1 test, especially non-small cell lung cancer (NSCLC) It is recommended for disease monitoring in the types of lung cancer of epithelium origin. Measurements performed at the beginning of the treatment and at the following periods reveal how the disease is diluted. Thus, clinical decision processes are guided more accurately.
In addition Consuming of the diseasecan help early notice of situations such as metastasis development or resistance to treatment. CYFRA 21-1’n’t a diagnostic test alone, for monitoring purposes It is important to emphasize that it is a biomarker used. Clinical story should be assessed together with imaging and other biochemical indicators.
Elecsys® CYFRA 21-1 Advantages of the test
- High sensitivity and personality: Home 19 accurately detects trailers.
- Fast result time: ECLIA Thanks to its technology, high sample efficiency and reliable result in a short time.
- Serial tracking: Allows you to monitor disease dynamics throughout the treatment process.
- Clinical decision support: Long-term patient monitoring provides reliable data to physicians.
Thanks to these advantages Elecsys® CYFRA 21-1lung cancer patients have become a valuable tool for personalized tracking.
Where to Supply? Why? Tilia Medical?
Elecsys® CYFRA 21-1 testTrusted in Turkey and nearby geography Tilia Medical available via. Tilia Medical, 2017 has been specialized in medical device and kit supply field since the year, offering quality-oriented and solution is a supplier.
Tilia MedicalThe main reasons for you to choose are:
- Roche authorized and reliable supplier of branded products Provides fast and complete delivery.
- Laboratory installations, device training, technical support and certified product consulting offers comprehensive services.
- For the European and Middle East market logistics infrastructureguarantees the orders from time to time.
- With expert staff product compliance, purpose of use and routing according to clinical needs provides.
